A5043927389- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- Bone Tumor Diagnosis and Treatments
- Molecular Biology Techniques and Applications
- Virus-based gene therapy research
- Cancer Cells and Metastasis
- Glioma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Childhood Cancer Survivors' Quality of Life
- Cancer Research and Treatments
- Peptidase Inhibition and Analysis
- Cell Adhesion Molecules Research
- RNA Research and Splicing
- Lymphoma Diagnosis and Treatment
- RNA modifications and cancer
- Acute Lymphoblastic Leukemia research
- Gastrointestinal Tumor Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Acute Myeloid Leukemia Research
- Tumors and Oncological Cases
The University of Texas MD Anderson Cancer Center
2017-2025
Harrogate and District NHS Foundation Trust
2020-2023
Scripps MD Anderson Cancer Center
2023
Albert Einstein College of Medicine
2010-2019
Montefiore Medical Center
2012-2019
Tulane University
2019
Children's Hospital at Montefiore
2011-2017
Harrogate District Hospital
2015
Emory University
2014
St James's University Hospital
2011-2014
Abstract Osteosarcoma patient survival has remained stagnant for 30 years. Novel therapeutic approaches are needed to improve outcomes. We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined tumor immune microenvironment assess prognostic utility in osteosarcoma. PD-L1 osteosarcoma was two cohorts using immunohistochemistry (IHC) (n = 48, n 59) validated quantitative real time PCR 21) western blotting 9). IHC used determine presence infiltrating lymphocytes...
BACKGROUND Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on cell surface some tumors, immunotherapy has resulted in improved neuroblastoma. In current study, expression pattern GD2 was examined osteosarcoma. METHODS Immunohistochemistry performed samples from at time initial biopsy, definitive surgery, and disease recurrence. The intensity location staining were scored. Cell‐based...
Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve these patients. We sought evaluate prevalence clinical significance of newest immune checkpoint, HHLA2, HHLA2 protein expression was evaluated primary tumor specimens metastatic disease using an osteosarcoma microarray (TMA) (n = 62). The association presence infiltrating lymphocytes (TILs) five-year-event-free-survival were...
The neutropenic diet (ND) is prescribed to avoid introduction of bacteria into a host's gastrointestinal tract and reduce infection. Due lack evidence support the ND, there continues be debate among pediatric oncologists regarding its usefulness. This prospective randomized controlled trial evaluated difference in infection rates oncology patients Food Drug Administration approved food safety guidelines (FSGs) versus ND plus FSGs during one cycle chemotherapy.Pediatric receiving cancer...
Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none US Food and Drug Administration-approved adults.
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on cell surface various types, including osteosarcomas.In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for expression via immunohistochemistry, of which 47 to express GD2. In matched patients, seen at initial biopsy was persist 100% tissues taken recurrence.GD2 upon recurrence. These results suggest a phase 2...
Abstract Osteosarcoma (OS), the most common primary cancer of bone, exhibits a high propensity for local invasion and distant metastasis. This study sought to elucidate role S phase kinase-associated protein (Skp2) in osteosarcoma metastasis explore flavokawain A (FKA), natural chalcone from kava extract, as potential Skp2 targeting agent preventing progression. was found be overexpressed multiple cell lines, including 5 standard 8 patient-derived lines. Patients whose tumors expressed...
Cure rates for children and young adults with osteosarcoma have remained stagnant over the past three decades. Targeting glycoprotein non-metastatic b (GPNMB) antibody-drug conjugate glembatumumab vedotin has improved outcomes patients melanoma breast cancer. The potential utility of targeting GPNMB in was explored.GPNMB protein expression evaluated by immunohistochemistry human tumor samples enzyme-linked immunosorbent assay (ELISA) cell lines. mRNA measured quantitative PCR primary Surface...
// David M. Barris 1, * , Shoshana B. Weiner Robert A. Dubin 2 Michael Fremed 1 Xusheng Zhang Sajida Piperdi 3 Wendong Shahina Maqbool Jonathan Gill 4 Roth Bang Hoang 5 Geller Richard Gorlick and Daniel Weiser 6, 7 Department of Genetics Pediatrics, Albert Einstein College Medicine, Bronx, NY, USA Computational Genomics Core, Montefiore Medical Center, Division University Texas MD Anderson Cancer Houston, Texas, Orthopedic Surgery, 6 Hematology/Oncology, Children’s Hospital at...
Abstract Immunoconjugates targeting cell-surface antigens have demonstrated clinical activity to enable regulatory approval in several solid and hematologic malignancies. We hypothesize that a rigorous comprehensive surfaceome profiling approach identify osteosarcoma-specific can similarly development of effective therapeutics this disease. Herein, we describe an integrated proteomic transcriptomic proteins are highly expressed osteosarcoma but minimally on normal tissues. Using approach,...
Background Survival outcomes for patients with osteosarcoma (OS) have remained stagnant over the past three decades. Insulin-like growth factor 1 receptor (IGF1R) is over-expressed in a number of malignancies, and anti-IGF1R antibodies are currently being studied clinical trials. Understanding molecular aberrations which result increased tumor response to therapy could allow selection most likely benefit from IGF1R targeted therapy. Methods mRNA expression was assessed by RT PCR OS patient...
Abstract Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with may be referred enrollment in early-phase trials. This study aimed to investigate whether biomarker-matched clinical trials leads better outcomes advanced sarcoma. Experimental Design: In this retrospective analysis, investigational treatment characteristics and longitudinal survival were analyzed biopsy-confirmed enrolled...
Neuroblastoma (NB) is a deadly childhood disease that carries 50% chance of relapse for anyone in remission and similar level 5-year survival. We investigated the value our proprietary approach—cell surface vimentin (CSV) positive circulating tumor cells (CTC) to monitor treatment response predict NB patients under Phase II long-term preventative clinical trial. longitudinally analyzed peripheral blood samples from 93 27 cycles (~25 months) discovered presence CSV+ CTCs first two sequential...
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Although histologically defined by presence of osteoid, possesses lineage multipotency suggesting it could be derived from a cell anywhere on differentiation pathway between mesenchymal stem (MSC) mature osteoblast. To determine if preosteoblasts (pOB) origin differentiated MSCs were transformed with genetic elements. pOB same serially oncogenes hTERT, SV40 large T antigen H-Ras. Assays performed to...
Membrane protein leucine-rich repeat containing 15 (LRRC15) is known to be expressed in several solid tumors including osteosarcoma. ABBV-085, an antibody-drug conjugate against LRRC15, conjugated monomethyl auristatin E (MMAE), was studied osteosarcoma patient-derived xenografts (PDXs) by the Pediatric Preclinical Testing Consortium (PPTC). LRRC15 expression data were obtained from PPTC RNA-sequencing for PDX models. The TARGET database mined human Protein confirmed via IHC three Seven...